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Background: The continuation of trastuzumab beyond progression in combination with capecitabine as secondary
chemotherapy for HER2-positive metastatic breast cancer (MBC) prolongs progression-free survival without
a substantial increase in toxicity.
Patients and methods: A Markov cohort simulation was used to follow the clinical course of typical patients with
MBC. Information on response rates and major adverse effects was derived, and transition probabilities were
estimated, based on the results of the Breast International Group 03-05 clinical trial. Direct costs were assessed from
the perspective of the Swiss health care system.
Results: The addition of trastuzumab to capecitabine is estimated to cost on average an additional of €33 980
and to yield a gain of 0.35 quality-adjusted life years (QALYs), resulting in an incremental cost-effectiveness ratio of
€98 329/QALYs gained. Probabilistic sensitivity analysis showed that the willingness-to-pay threshold of €60 000/
QALY was reached in 12% of cases.
Conclusion: The addition of trastuzumab to capecitabine in MBC patients is more expensive than what is typically
regarded as cost-effective but falls within the value ranges found for established regimens in the treatment of MBC.
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introduction
The prognosis for breast cancer patients with HER2-
amplification (HER2+) has substantially improved since the
introduction of trastuzumab into routine clinical treatment
practice for metastatic disease. When added to first-line
chemotherapy regimens (anthracycline plus cyclophosphamide,
or paclitaxel) in a randomized, controlled trial, trastuzumab
demonstrated significant improvement in survival (25.1 versus
20.3 months) and objective response rate (50% versus 32%),
with acceptable additional toxicity [1]. Cardiotoxicity is the
main side-effect observed with trastuzumab treatment, in
particular when administered in combination with
anthracyclines [1]. Subsequently, trastuzumab-based
non-anthracycline chemotherapy has become a standard of care
in the first-line therapy of HER2+ patients with metastatic
disease. In a retrospective analysis, trastuzumab treatment
seems to reverse the poorer prognosis for metastatic HER2+
patients compared with HER2-negative patients [2].
Nevertheless, the majority of trastuzumab-treated patients
exhibit either de novo or acquired resistance to treatment or
have early relapse [3]. In these patients, conventional
chemotherapy, usually taxane based, is stopped and the patient
is switched to a second-line treatment. Recently, the
combination of lapatinib and capecitabine has been established
as an additional HER2-directed treatment option for this
group of patients. A significant prolongation of median time to
disease progression (8.4 versus 4.4 months for capecitabine
alone) could be achieved with this novel dual tyrosine kinase
inhibitor of HER1 and HER2 [4]. Empirically, however,
trastuzumab has been continued in many patients with disease
progression, mainly due to its favorable safety profile and the
assumption that progression was due to resistance to the
co-administered chemotherapeutic agent but not trastuzumab
itself [5]. Retrospective analyses provided some support for
this treatment approach, at a weak level of evidence [6–9].
These findings have recently been confirmed by the German
Breast Group 26/Breast International Group (BIG) 03-05
study, a randomized, controlled trial of trastuzumab treatment
in combination with capecitabine continued beyond
progression [10].
Given that cancer treatment costs have been increasing
rapidly during the past few years and will continue to do so, it
is essential to allocate the available resources as efficiently as
possible [11]. Cost-effectiveness analyses for HER2+ metastatic
breast cancer (MBC) have examined the role of trastuzumab as
a first-line treatment [12–15] and of lapatinib as a second-line
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treatment [16], but costs associated with trastuzumab beyond
progression have not yet been addressed.
The aim of this study is to examine the cost-effectiveness of
trastuzumab beyond progression from the perspective of the
Swiss health care system.
materials and methods
We constructed a Markov model to assess the cost-effectiveness of
treatment strategies for patients with HER2+ MBC who progressed during
treatment with trastuzumab. Chemotherapy with capecitabine alone was
compared with capecitabine plus continuation of trastuzumab. Clinically,
the modeling was based on the BIG 03-05 study [10]. Direct medical costs
were based on Swiss national tariffs and covered chemotherapy treatment,
major adverse events, laboratory tests and disease progression. The time
horizon of the analysis was lifelong. Costs were assessed from the
perspective of the Swiss health care system. Accordingly, indirect costs
were not considered. Costs are reported in Euros (€). An exchange rate of
€1.00 = CHF 1.52 was used (average exchange rate March 2009–October
2009). Utilities for the health states represented in the model were obtained
from the literature [16–18]. Costs and benefits were not discounted given
the short life expectancy of the patient population studied.
Patients were included in the BIG 03-05 study if they had pathologically
confirmed, HER2++ (by immune histochemistry or FISH), locally advanced
or MBC, if the duration of previous trastuzumab treatment was 12 weeks or
greater and if the time since the end of the last trastuzumab cycle was <6
weeks [10]. Patients could have received up to one chemotherapy drug for
metastatic disease. Patients with a Karnofsky performance status of less than
60%; a life expectancy of <3 months or inadequate hematologic, renal,
hepatic, or cardiac function (left ventricular ejection fraction of <50%) were
excluded. Enrolled patients were randomly assigned to receive either
capecitabine 2500 mg/m2 (1250 mg/m2 twice-daily) on days 1 through 14
followed by 1 week of rest or the same capecitabine regimen plus 6 mg of
trastuzumab per kilogram body weight (BW), given as a 30-minute infusion
every 3 weeks. The calculated capecitabine dose was approximated by the
closest possible dose achievable with 500-mg and 150-mg tablets (Table 1).
Patients received the assigned therapy until disease progression or until
unacceptable toxicity occurred.
The primary outcome measure of this analysis was the incremental
cost-effectiveness ratio (ICER), expressed as cost per quality-adjusted life
year (QALY) gained, of continuing trastuzumab in combination with
capecitabine, compared with capecitabine alone, for advanced MBC that
progressed under trastuzumab therapy. ICERs results were compared with
a willingness-to-pay threshold of €60 000/QALY [24].
Secondary outcome measures included ICERs for subgroups of patients
defined by different weight and body surface area (BSA) categories.
A theoretical cost-effective price was calculated for multi-dose vials of
trastuzumab (440 mg per vial).
One-way sensitivity analyses and probabilistic sensitivity analyses (Monte
Carlo simulation) were carried out to test the robustness of the results.
model structure
The structure of the Markov model is shown in Figure 1. The model
comprises three mutually exclusive health states: stable/responsive disease,
disease progression and death. Cycle length was 3 weeks, to match the
duration of chemotherapy cycles. At model entry, all patients were in the
stable/responsive disease state. At the end of each cycle, they could stay in
the stable/responsive disease state or move to the progressive disease state.
Patients with progressive disease could remain in this state or die. We
assumed constant hazards over time and used the median time spent in
each stage to estimate hazard rates for the control arm, based on the
following formula: hazard rate = 2ln(0.5)/(median time in state). Hazard
rates were subsequently converted into Markov state transition
probabilities, taking into account the Markov cycle length of 3 weeks. In
order to model survival in the treatment arm, control arm hazard rates were
multiplied with hazard ratios (HRs) for time to progression (TtP) and the
median TtP [10]. HR for time from progression to death, which was not
available from the publication, was kindly provided by the investigators
(G. von Minckwitz).
model inputs
clinical data. The effectiveness data used in the modeling were based on the
German Breast Group 26/BIG 03-05 study, as described above. In this
study, no significant differences in the occurrence of grade 3–4 adverse
events were reported. Therefore, only costly adverse events were taken into
account in the modeling, namely suspected myocardial infarction (one
patient in capecitabine + trastuzumab arm) and pericardium effusion (one
patient in capecitabine + trastuzumab arm; Table 2).
Treatment delays occurred in both arms in an almost equal percentage of
patients (8% capecitabine group, 9.3% capecitabine + trastuzumab group).
As no data were available on the duration of these delays, no correction was
applied in the modeling. As a reduction of capecitabine dose became
necessary in an almost equal percentage of patients in both arms (58.9% of
the patients in the capecitabine group and in 57.3% in the capecitabine plus
trastuzumab group) this was not corrected for in the model. Due to lack of
available detail, this was not corrected for in the model. Trastuzumab doses
were not reduced in the study.
utilities. Preference-based utility scores for stable and progressive disease
were derived from the literature [16–18]. The utility assumed for stable
disease was 0.7 (range 0.5–0.8) and was both used for the control and
treatment arm as no difference in quality of life for adding trastuzumab to
capecitabine was expected [9, 25]. For time in progression, a utility of 0.5
(range 0.45–0.72) was used.
medical resource use. Assessment of medical resource use was based on the
BIG 03-05 study [10] and on a study of the resource use and costs for
patients with MBC conducted at the University Hospital of Zurich [23].
The types of medical resources included in the model were study
medication (including prescription, preparation and administration),
laboratory tests, medical resources used during disease progression and
costs for major adverse events [22] (Table 1).
Capecitabine dosage and number of tablets was calculated for five BSA
categories and based on the prescription information given on the Swiss
label for Xeloda (Roche Pharmaceuticals, Basel, Switzerland) [19].
Twice-daily administration was assumed. For the five BSA categories,
corresponding mean BWs were established on the basis of data from
398 European women with breast cancer [26] and used to calculate
corresponding trastuzumab (Herceptin; Roche Pharmaceuticals) dosages.
It was assumed that most of the central pharmacies in Swiss hospitals
treating breast cancer patients provide the exact amount of trastuzumab
required and that any leftovers are saved for later use, eliminating the
necessity to correct for wastes.
In the BIG 03-05 study, the actual duration of treatment administration
was shorter than the observed TtP in both arms. In the assessment of medical
resource use, treatment duration was therefore corrected for the number
of administered treatment cycles to fit the real data. In the control arm,
patients received six cycles of capecitabine in the median, while, numerically,
median TtP would have corresponded to 8.1 cycles. In the treatment arm,
the median cycle number for capecitabine and trastuzumab was 9 and
the median TtP would have corresponded to 11.8 cycles. Although
trastuzumab was continued after discontinuation of capecitabine in 16
patients (20.8%), no additional correction was made for this monotherapy.
The median-based correction was assumed to be comprehensive.
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unit costs. Unit costs for treatment medication and concomitant treatments
(Table 1) were taken from Swiss national drug price and tariff lists [19–21].
The per-cycle cost of treatment after disease progression was based on the
total resource use observed during the first 5 years of treatment of patients
with MBC as described by Dedes et al. [23]. This single-center experience is
the best currently available Swiss source on the topic, and reported costs are
comparable with data from other health care systems [27, 28].
sensitivity analysis
To assess the impact of statistical uncertainty around key model inputs,
a series of univariate sensitivity analyses were carried out for the middle
body surface area–body weight (BSA-BW) group (66 kg, 1.67–1.78 m2), as
this group includes the median BSA of 1.76 m2 as calculated from the data
of 398 European women with breast cancer [26] or for women with solid
tumors (BSA 1.74 m2) as described by Miller et al. [29]. In addition,
Table 1. Unit and cycle costs
Study treatment Body weight (kg)–body surface (m2)
Unit costs 51 kg,
1.39–1.52
58 kg,
1.53–1.66
66 kg,
1.67–1.78
75 kg
1.79–1.92
84 kg,
1.93–2.06
Capecetabine—Xeloda [19] Tablets per day
Tablet at 150 mg/60 tablets €77.43
One tablet €1.29 2· 2 0 2· 1 2· 2
Tablet at 500 mg/120 tablets €462.40
One tablet €3.85 2· 3 2· 4 2· 4 2· 4 2· 5
Total dose per day 3600 mg 4000 mg 4300 mg 4600 mg 5000 mg
Costs per cycle €360 €432 €468 €504 €540
Trastuzumab—Herceptin
[19]
Trastuzumab 6 mg/kg, mg/cycle
440 mg multiple dosing €2310.39 306 mg 348 mg 397 mg 450 mg 504 mg
1 mg €5.25
Costs per cycle €1611 €1828 €2084 €2363 €2646
Other resources/treatments
Nadir blood count
1· per cycle [20]
€89.24 Costs per cycle Treatment and control arm €89.24
Chemotherapy prescription
and preparation
1· per cycle [21]
€25.49 Costs per cycle Treatment arm only €25.49
Chemotherapy administration
1· per cycle [21]
€52.90 Costs per cycle Treatment arm only €52.90
Treatment of heart failure per
month [22]
€354.00 Costs per cycle Treatment arm only €245.00
Treatment costs while in
progression per month [23]
€1109.26 Costs per cycle Treatment and control arm €768.00
Echocardiography ones per stage [21] €245.00 Treatment arm only
One cycle = 3 weeks.
Figure 1. Structure of Markov model.
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probabilistic sensitivity analyses for all BS-BW groups were carried out.
Additional scenario analyses were used to assess the impact of assumptions
not primarily related to statistical uncertainty.
univariate sensitivity analysis. In univariate sensitivity analysis, median
survival times, HRs, utility parameters and median numbers of treatment
cycles as well as the costs of follow-up treatment were varied according to
the distributions described in Table 2. The frequency of occurrence of the
adverse event of heart failure and the performance of echocardiographies
were also varied. In the absence of confidence intervals (CIs), the base-case
values for these parameters were varied by 630%.
probabilistic sensitivity analysis. Probabilistic sensitivity analyses (second-
order Monte Carlo simulation) for all separate BSA-BW groups were based
on the parameter distributions described in Table 2. For each BW-BS
group, the probability of being cost-effective, based on a willingness-to-pay
threshold of €60 000, was calculated.
additional scenario analyses. Drug prices may decrease over time due to
price negotiations or expiring patent protection. As the original clinical
effectiveness data from the BIG study [10] is promising and clinical
relevant, acceptability curves as well as cost-effective prices for trastuzumab
were calculated. These calculations were carried out for all BW-BS groups
and using the base-case inputs for all other model input parameters.
model validation
The model was calibrated to match the original survival results of the BIG
03-05 study. Trackers for progression-free survival, overall survival and
number of cycles were included in the model to assess correct reproduction
of the original data. Additionally, all model outputs were reviewed for
plausibility and key input parameters were subjected to extreme variation to
test whether the model outputs behaved as expected.
technical implementation
The model was implemented and all Markov cohort and Monte Carlo
analyses were carried out using TreeAge Pro Suite 2009 (TreeAge
Software Inc., Williamstown, MA). Probabilistic sensitivity analyses were
based on 5000 sets of randomly drawn input parameters.
results
After calibration, the effectiveness model outputs were
comparable with the original clinical data of the BIG 03-05
study as shown in Table 3.
In the base-case analysis, the model indicated that continuing
trastuzumab in combination with capecitabine, compared with
capecitabine alone, in patients with locally advanced or MBC
that progressed under trastuzumab therapy, leads to a gain of
0.35 QALYs per patient at an additional cost ranging from
€27 502 (51 kg, 1.39–1.52 m2) to €41 456 (84 kg, 1.93–2.06 m2).
Therefore, ICER for the continuation of trastuzumab in
combination with capecitabine compared with capecitabine
alone ranged from €79 581/QALY to €119 960/QALY gained,
for the lowest to highest BW-BS groups.
sensitivity analyses
Univariate sensitivity analysis was carried out for the middle
BW-BS group (66 kg, 1.67–1.78 m2). The base-case ICER
for this group was €98 329/QALY. Varying the HR for time
from progression to death had the highest impact on the ICER
and led to an ICER below the willingness-to-pay threshold of
€60 000 for the lowest HR (0.64) input used. The second-most
influential parameter was the HR for TtP. Reducing the
number of treatment cycles in the trastuzumab + capecitabine
arm reduced the ICER to €67 847/QALY; however, such
a reduction would possibly impact negatively on the size of the
clinical effect and therefore, such a low ICER may not be
achievable. All other univariate sensitivity analysis results are
summarized in a Tornado diagram (Figure 2). None of the
other parameters tested resulted in an ICER below the
willingness-to-pay threshold of €60 000.
Probabilistic sensitivity analyses resulted in a 26.94%
probability of meeting the €60 000/QALY willingness-to-pay
threshold in the lowest body weight–body surface group (BW-BS
Table 2. Distributions
Variable Distribution Base case
% Patients with echocardiography Triangular 30% Varied 630%: min–max 21%–39%
% Patients with heart failure Triangular 2.5% Varied 630%: min–max 1.8%–3.3%
Hazard ratio, time from progression to death Lognormal 1.035 95% CI 0.64–1.68
Hazard ratio, time to progression Lognormal 0.69 95% CI 0.48–0.97
Median number of treatment cycles, control arm Triangular 6 cycles Varied 630%: min–max 4.2–7.8 cycles
Median number of treatment cycles, treatment arm Triangular 9 Varied 630%: min–max 6.3–11.3 cycles
Time from progression to death, control arm Gamma 12.72 month 95% CI 9.67–16.75 month
Time to progression, control arm Gamma 5.6 month 95% CI 4.2–6.3 month
Treatment costs per cycle during progression Triangular €768 Varied 630%: min–max €539–998
Utility during stable Triangular 0.7 Range: min–max 0.5–0.8
Utility during progression Triangular 0.5 Range: min–max 0.45–0.72
CI, confidence interval.
Table 3. Median time to progression and overall survival in model and
original data
Model Original data
Time to progression Control 5.89 month 5.6 month
Treatment 7.96 month 8.2 month
Overall survival Control 20.42 month 20.4 month
Treatment 25.96 month 25.5 month
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66 kg, 1.67–1.78 m2 see Figure 3). The lowest probability (4.7%)
of meeting the €60 000/QALY willingness-to-pay threshold was
found for the highest BW-BS group (Table 4, Figure 4).
cost-effective trastuzumab price
In an additional analysis, cost-effective price for trastuzumab
was calculated for all five BW-BS groups. Today the price for
a 440-mg vial of trastuzumab is €2310. In order to reduce the
ICER to the willingness-to-pay threshold of €60 000,
a reduction of 30%–60% would be required, resulting in a price
per vial between €1639 and €940, depending on BW and BSA of
the patients (Figure 5).
discussion
The addition of trastuzumab to capecitabine alone as a second-
line treatment of HER2+ MBC patients who progress under
trastuzumab-containing first-line chemotherapy results in
a gain of 0.35 QALYs, based on the BIG 03-05 study and
according to our model. This survival advantage is associated
with an additional lifetime cost of €27 502–€41 456 per
patient, resulting in an average ICER of €98 500/QALY
gained (range €79 581–119 960/QALY according to BW). The
additional costs associated with the combination treatment
are mainly the acquisition costs of trastuzumab, whereas the
cost of administration and treatment of side-effects is
negligible.
Available cost-effectiveness data on anti-HER2-directed
drugs for MBC are limited. Norum et al. [12] published an
analysis on trastuzumab for the first-line use from the
perspective of the Norwegian health care system (with an ICER
ranging from €63 137 to €162 417). For lapatinib use in the
second line of treatment, Le and Hay [16] reported an ICER of
USD 166 113 (€110 184), based on the clinical trial by Geyer
et al. [4]. Le and Hay carried out their cost-utility analysis for
the USA health care system. Although the inclusion criteria for
this study and the BIG 03-05 study were similar, baseline
characteristics of the included patients differed. For example,
median age in the capecitabine-alone arm of the lapatinib trial
was 51 years compared with 59 years in the trastuzumab trial.
The percentage of patients with hormone receptor-positive
cancers in the control arms was 47% versus 62%, respectively
[4, 10]. The resulting median time for progression was shorter
in the capecitabine-alone arm of the lapatinib trial
(4.4 months) compared with the trastuzumab trial (5.6
months), reflecting the fact that patients with more aggressive
breast cancers were included. Compared with targeted first-line
treatment of HER2-negative cancers with bevacizumab
(ICER of €189 500/QALY gained), our results for trastuzumab
beyond progression are substantially more favorable [23].
Figure 3. Monte Carlo for women with mean body weight of 66 kg and
a body surface of 1.67–1.78 m2. ICE, incremental cost effectiveness.
Figure 2. Tornado plot univariate sensitivity analyses for women with mean body weight of 66 kg and a body surface of 1.67–1.78 m2. BS, body surface;
BW, body weight; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; WTP, willingness to pay.
Annals of Oncology original article
Volume 21 |No. 11 |November 2010 doi:10.1093/annonc/mdq250 | 2165
In probabilistic sensitivity analysis, the probability to meet
a willingness-to-pay threshold of €60 000 was between 4.7%
and 26.9%, depending on the BSA and weight of the patients
analyzed. HRs for time from progression to death and for TtP
were the most influential parameters in univariate sensitivity
analysis, driven by relatively wide CIs due to limited patient
numbers in the BIG 03-05 study. They impacted on cost but
more strongly on clinical effect estimates, i.e. the denominator
of the cost-effectiveness formula. The median number of
treatment cycles in the trastuzumab plus capecitabine arm was
second-most influential. Considering that the BIG 03-05 study
showed a substantial clinical benefit and that we found, for
the continuation of trastuzumab beyond progression, a
5%–27% probability of cost-effectiveness better than the
threshold of €60 000/QALY, the ICER range of €79 581–
119 960/QALY should be interpreted with care. Judging the
BIG 03-05 study only in relation to costs may undervalue the
results of the study. It would, e.g. be relevant to calculate
a parallel set of ICER results using patient-derived instead of
general population-based health state valuations. However, this
is currently precluded by a lack of appropriate input data.
An additional scenario analysis showed that decreasing the
cost of trastuzumab by 30%–60% (depending on BW and BSA)
would result in ICERs below the threshold of €60 000/QALY.
Reliance on data from a single randomized clinical trial [10]
is the most important limitation of this analysis. The BIG 03-05
study, on which this cost-utility analysis had to rely on, had
some particular limitations. For example, the initial protocol
intended to randomly assign 482 patients in total but the trial
was closed with 156 patients only [30]. One reason was the slow
study accrual of patients and the other the early closure of the
trial due to the availability of the lapatinib plus capecitabine
data [4, 30]. Furthermore, another main criticism of this study
is a possible investigator bias as responses or progressions
defined by the RECIST criteria lacked independent assessment
of responses [30]. Nevertheless, this trial is the best available
evidence on which continuation of trastuzumab administration
despite progression, a commonly practiced approach, can be
based. Given that new anti-HER2-directed treatments are
Table 4. Base-case incremental cost-effectiveness ratios
BS-BW Strategy Costs, € Incremental
costs, €
Effect Incremental
effect
Cost/effect ICER Probability
cost-effectivea, %
66 kg, 1.67–1.78 m2 Control 23 217 2.06 YR €11 253/YR
Treatment 57 198 33 980 2.64 YR 0.58 YR €21 654/YR 58 762 €/YR
Control 23 217 1.17 QALY €19 854/QALY
Treatment 57 198 33 980 1.51 QALY 0.35 QALY €37 756/QALY 98 329 €/QALY 11.98
51 kg, 1.39–1.52 m2 Control 22 263 1.17 QALY €19 038/QALY
Treatment 49 764 27 502 1.51 QALY 0.35 QALY €32 849/QALY €79 581/QALY 26.94
58 kg, 1.53–1.66 m2 Control 22 899 1.17 QALY €19 582/QALY
Treatment 53 462 30 563 1.51 QALY 0.35 QALY €35 290/QALY 88 439 /QALY 18.5
75 kg, 1.79–1.92 m2 Control 23 535 1.17 QALY €20 127/QALY
Treatment 61 228 37 692 1.51 QALY 0.35 QALY €40 416/QALY €109 070 /QALY 7.66
84 kg, 1.93–2.06 m2 Control 23 853 1.17 QALY €20 399/QALY
Treatment 65 309 41 456 1.51 QALY 0.35 QALY €43 110/QALY €119 960 /QALY 4.76
aProbabilistic sensitivity analysis.
BW, mean body weight; BS, body surface; ICER, incremental cost-effectiveness ratio.
Figure 4. Acceptability curve for all body weight/body surface groups.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted
life year.
Figure 5. Costs of trastuzumab to be cost-effective, all body weight–body
surface groups. ICER, incremental cost-effectiveness ratio; QALY, quality-
adjusted life year.
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beginning to be tested for these patients [31], no further
randomized, controlled trial-based evidence on continuation of
trastuzumab treatment beyond progression is expected to be
published in the near future. In the absence of additional trial
data, a relevant amount of uncertainty remains. It should also
be kept in mind that randomized clinical trial-based
cost-effectiveness results may overestimate real-world
effectiveness.
Some model input data had to be based on assumptions due to
a lack of published data. For example, 58.9% of the patients in the
capecitabine group and 57.3% in the capecitabine plus
trastuzumab group had dose reductions for capecitabine. The
extent and time of dose reduction in both groups, however, were
not reported. Therefore, we assumed no difference between study
arms and implemented no correction in the model.
When implications of cost-effectiveness and cost-utility
results for reimbursement decisions are discussed, reference to
cost-effectiveness thresholds (compared with different
interventions or based on societal willingness-to-pay) is usually
made. However, in Switzerland as well as most other countries,
no such thresholds have formally been defined. In the USA
threshold values of USD 50 000–100 000 per QALY gained are
usually regarded as acceptable [32–34]. Taking into account
differences in purchasing power, this range is roughly
equivalent to CHF 50 000–100 000 (mean exchange rate 2009)
or €32 900–65 800/QALY gained in Switzerland [35]. This
threshold corresponds to 0.9–1.8 times the Swiss gross
domestic product per capita. In the UK a factor of 1.4–2.1 times
the gross domestic product per capita has tentatively been
estimated as the threshold being used by the National Institute
of Clinical Excellence.
In conclusion, in the patient group studied, administration
of trastuzumab and capecitabine after progression under
trastuzumab-containing chemotherapy is more expensive than
what is typically regarded as cost-effective. The cost-
effectiveness ratios identified, however, fall within the value
ranges found for established regimens in the treatment of MBC,
such as first-line trastuzumab plus chemotherapy, as well as
second-line lapatinib plus chemotherapy, and are more
cost-effective than first-line bevacizumab.
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